Feng‐Ming Tien

723 total citations
27 papers, 351 citations indexed

About

Feng‐Ming Tien is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Feng‐Ming Tien has authored 27 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 14 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Feng‐Ming Tien's work include Acute Myeloid Leukemia Research (16 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers) and Lymphoma Diagnosis and Treatment (5 papers). Feng‐Ming Tien is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers) and Lymphoma Diagnosis and Treatment (5 papers). Feng‐Ming Tien collaborates with scholars based in Taiwan, United States and Canada. Feng‐Ming Tien's co-authors include Hwei‐Fang Tien, Jih‐Luh Tang, Ming Yao, Wen‐Chien Chou, Hsin‐An Hou, Chien‐Yuan Chen, Cheng‐Hong Tsai, Wang‐Huei Sheng, Chien‐Chin Lin and Shang‐Yi Huang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Nutrients.

In The Last Decade

Feng‐Ming Tien

23 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Feng‐Ming Tien Taiwan	12	184	105	81	80	71	27	351
Elisa Cerqui Italy	9	203 1.1×	91 0.9×	83 1.0×	59 0.7×	50 0.7×	19	285
Gabriela Rodríguez‐Macías Spain	11	166 0.9×	94 0.9×	64 0.8×	73 0.9×	41 0.6×	30	361
Federica Lessi Italy	8	139 0.8×	89 0.8×	94 1.2×	137 1.7×	65 0.9×	30	377
José Falantes Spain	10	198 1.1×	88 0.8×	44 0.5×	63 0.8×	73 1.0×	29	291
Fumihiko Monma Japan	13	317 1.7×	112 1.1×	120 1.5×	89 1.1×	93 1.3×	35	496
M Vigier France	9	150 0.8×	33 0.3×	120 1.5×	147 1.8×	59 0.8×	12	326
Anna Staffas Sweden	11	208 1.1×	226 2.2×	33 0.4×	76 0.9×	32 0.5×	25	434
Josefina Serrano Spain	15	481 2.6×	118 1.1×	99 1.2×	97 1.2×	40 0.6×	39	628
Azlan Husin Malaysia	14	171 0.9×	140 1.3×	112 1.4×	74 0.9×	29 0.4×	51	471
JM Vossen Netherlands	11	341 1.9×	63 0.6×	61 0.8×	102 1.3×	91 1.3×	15	511

Countries citing papers authored by Feng‐Ming Tien

Since Specialization

Citations

This map shows the geographic impact of Feng‐Ming Tien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng‐Ming Tien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng‐Ming Tien more than expected).

Fields of papers citing papers by Feng‐Ming Tien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng‐Ming Tien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng‐Ming Tien. The network helps show where Feng‐Ming Tien may publish in the future.

Co-authorship network of co-authors of Feng‐Ming Tien

This figure shows the co-authorship network connecting the top 25 collaborators of Feng‐Ming Tien. A scholar is included among the top collaborators of Feng‐Ming Tien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feng‐Ming Tien. Feng‐Ming Tien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Yu‐Wen, Hao-Yang Lin, Chien‐Chin Lin, et al.. (2025). Comprehensive Characterization of Overt Myelofibrosis in an Asian Cohort: Phenotype, Mutation Landscape and Discordance Among Scoring Systems. Hematological Oncology. 43(1). e70040–e70040.

Lin, Chien‐Chin, Cheng‐Hong Tsai, Feng‐Ming Tien, et al.. (2025). Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends. Clinical Lymphoma Myeloma & Leukemia. 25(6). e336–e347.e14.

Tien, Feng‐Ming, Chi‐Yuan Yao, Cheng‐Hong Tsai, et al.. (2024). Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations. Blood Cancer Journal. 14(1). 8 indexed citations

Lin, Chien‐Chin, Cheng‐Hong Tsai, Feng‐Ming Tien, et al.. (2024). Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms. Blood Cancer Journal. 14(1). 57–57. 7 indexed citations

Tien, Feng‐Ming & Hsin‐An Hou. (2024). CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment. International Journal of Hematology. 120(5). 541–547. 2 indexed citations

Tsai, Cheng‐Hong, Feng‐Ming Tien, Mei‐Hsuan Tseng, et al.. (2023). Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification. Blood Cancer Journal. 13(1). 120–120. 12 indexed citations

Tsai, Cheng‐Hong, Feng‐Ming Tien, Yuan‐Yeh Kuo, et al.. (2023). Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood Cancer Journal. 13(1). 4–4. 17 indexed citations

Lin, Chien‐Chin, Cheng‐Hong Tsai, Feng‐Ming Tien, et al.. (2023). Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification. American Journal of Hematology. 98(3). 398–407. 6 indexed citations

Lin, Chien‐Chin, Cheng‐Hong Tsai, Feng‐Ming Tien, et al.. (2023). Clinico-Genetic and Prognostic Analyses of 635 Patients with Myelodysplastic Neoplasms Based on the 2022 World Health Organization Classification. Blood. 142(Supplement 1). 1878–1878. 1 indexed citations

10.

Tsai, Cheng‐Hong, Chien‐Chin Lin, Feng‐Ming Tien, et al.. (2023). Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. American Journal of Hematology. 98(5). 760–769. 19 indexed citations

11.

Yao, Chi‐Yuan, et al.. (2023). A case of acute myelomonocytic leukemia morphologically mimicking lymphoblastic leukemia. SHILAP Revista de lepidopterología. 11(4). e7146–e7146. 1 indexed citations

12.

Tien, Feng‐Ming, Hsuan‐Hsuan Lu, Shu‐Yung Lin, & Hsing-Chen Tsai. (2023). Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. Journal of Biomedical Science. 30(1). 3–3. 25 indexed citations

13.

Lin, Chien‐Chin, Chi‐Yuan Yao, Yuan‐Yeh Kuo, et al.. (2022). Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes. Hematological Oncology. 41(3). 463–473.

14.

Tsai, Cheng‐Hong, Jih‐Luh Tang, Feng‐Ming Tien, et al.. (2021). Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Advances. 5(10). 2456–2466. 38 indexed citations

15.

Wang, Yuwen, Cheng‐Hong Tsai, Hsin‐An Hou, et al.. (2021). Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. Annals of Hematology. 101(2). 349–358. 15 indexed citations

16.

Wang, Yuwen, Cheng‐Hong Tsai, Chien‐Chin Lin, et al.. (2020). Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Annals of Hematology. 99(3). 501–511. 55 indexed citations

17.

Chen, Chien‐Yuan, Aristine Cheng, Feng‐Ming Tien, et al.. (2019). Chronic disseminated candidiasis manifesting as hepatosplenic abscesses among patients with hematological malignancies. BMC Infectious Diseases. 19(1). 635–635. 16 indexed citations

18.

Tien, Feng‐Ming, Cheng‐Hong Tsai, Jia‐Hau Liu, & Chien‐Ting Lin. (2019). Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan. Journal of the Formosan Medical Association. 118(10). 1466–1470. 3 indexed citations

19.

Chen, Chien‐Yuan, Feng‐Ming Tien, Aristine Cheng, et al.. (2018). Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. BMC Gastroenterology. 18(1). 6–6. 16 indexed citations

20.

Chen, Chien‐Yuan, Feng‐Ming Tien, Wang‐Huei Sheng, et al.. (2017). Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008–2013. International Journal of Antimicrobial Agents. 49(3). 272–281. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact